Academic Journal
Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer
| العنوان: | Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer |
|---|---|
| المؤلفون: | Nara, K., Taguchi, A., Yamamoto, T., Hara, K., Tojima, Y., Honjoh, H., Nishijima, A., Eguchi, S., Miyamoto, Y., Sone, K., Mori, M., Takada, T., Osuga, Y. |
| المساهمون: | Department of Economics, University of Arizona |
| المصدر: | International Journal of Clinical Oncology |
| بيانات النشر: | Springer |
| سنة النشر: | 2023 |
| المجموعة: | The University of Arizona: UA Campus Repository |
| مصطلحات موضوعية: | Adverse event, Heterogeneous treatment effect, Histology, Platinum-free interval, Platinum-resistant ovarian cancer |
| الوصف: | Background: Single-agent chemotherapy with or without bevacizumab (Bev) is a standard therapy for platinum-resistant ovarian cancer (PR-OC). However, there is a lack of literature on chemotherapy agent selection in heterogenous PR-OC. Therefore, we aimed to clarify the heterogeneous treatment effects of each chemotherapy agent. Methods: Patients who underwent single-drug chemotherapy agents or Bev combination therapy for PR-OC between January 2009 and June 2022 were included in this study. We assessed the impact of each chemotherapy agent on the time to treatment failure (TTF) according to histological type, platinum-free interval (PFI), and Bev usage. Results: A total of 158 patients received 343 different chemotherapy regimens. In patients with clear cell carcinoma/mucinous carcinoma (CC/MC), gemcitabine (GEM) had the strongest effect with a median TTF of 5.3 months, whilst nedaplatin (NDP) had the lowest effect with a median TTF of 1.4 months. In contrast, in the non-CC/MC group, irinotecan (CPT-11) and NDP had a better TTF than GEM and pegylated liposomal doxorubicin (PLD). There were notable differences in the treatment efficacy of NDP according to PFI. Specifically, NDP prolonged the TTF in patients with a PFI ≥ 3 months. Compared with GEM alone, GEM + Bev tended to prolong the TTF more effectively; however, an additive effect was not observed with PLD + Bev. Conclusions: This study demonstrated that the effect of chemotherapy agents differed according to the tumor and background characteristics of the patient. Our findings will improve selection of effective therapies for patients with PR-OC by considering their background characteristics. © 2023, The Author(s). ; Open access article ; This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1341-9625 37347381 |
| Relation: | Nara, K., Taguchi, A., Yamamoto, T. et al. Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer. Int J Clin Oncol 28, 1207–1217 (2023). https://doi.org/10.1007/s10147-023-02367-1; http://hdl.handle.net/10150/674006; International Journal of Clinical Oncology |
| DOI: | 10.1007/s10147-023-02367-1 |
| الاتاحة: | http://hdl.handle.net/10150/674006 https://doi.org/10.1007/s10147-023-02367-1 |
| Rights: | © The Author(s) 2023. This article is licensed under a Creative Commons Attribution 4.0 International License. ; https://creativecommons.org/licenses/by/4.0/ |
| رقم الانضمام: | edsbas.E73BEF6C |
| قاعدة البيانات: | BASE |
| تدمد: | 13419625 37347381 |
|---|---|
| DOI: | 10.1007/s10147-023-02367-1 |